Source: Industry Bnet
GlaxoSmithKline’s Q2 2009 results, released a few days ago, were well received but within the company’s disclosures and investor presentations were some sobering statistics on the ongoing damage that generics are doing to the company, and the limited progress of its cost-reduction programs.
The basics: Revenue rose 15 percent to £6.7 billion, net income was £1.5 billion.
This chart shows first-half sales of GSK drugs affected by generics. Last year, the company sold £1.2 billion of those brands, such as Flonase and Paxil. This year, GSK sold only £437 million, a 65 percent decline.
Read more and see chart here
Fid
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING
Zantac Lawsuit
Researching drug company and regulatory malfeasance for over 16 years
Humanist, humorist
Please contact me if you would like a guest post considered for publication on my blog.
No comments: